Volnay Therapeutics

Volnay Therapeutics is a biotechnology company focused on accelerating the development of novel gene and cell therapies. With a team experienced in drug development, Volnay identifies promising therapeutic assets and innovative enabling technologies, providing funding and operational support to advance these initiatives. The company aims to create value for investors and patients by prioritizing capital efficiency, economic viability, and manufacturing innovation.

Top Sectors

Therapeutics Healthcare Biotechnology Clinical Trials Pharmaceuticals Show more

Top Stages

Series A Early Venture Stage

https://www.volnaytx.com

https://crunchbase.com/organization/volnay-therapeutics

Johannes Fruehauf

President and Co-Founder

1 past transactions

March Biosciences

Series A in 2024

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.